Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

TNYA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Tenaya Therapeutics, Inc.NASDAQ: TNYA

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin at -8565.3%

Net margin was -8565.3% in Q1 FY2026. On a trailing-twelve-month basis it was -36891.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-8565.3%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
-36891.1%— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How TNYA compares with its peers on the latest reported figures

  • TNYA's LTM Mar 2026 net margin of -36891.1% is the lowest of the 9 companies compared; the peer median is -392.5%.
TNYA Competitors Peer median
Net Margin for TNYA and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026454.9% —+4030.4 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-89.6% +60.0 pp+16.0 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-266.9% +75.4 pp+325.9 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-319.6% -193.1 pp-183.1 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-465.3% +1360.8 pp—
PYXSPyxis Oncology, Inc.LTM Mar 2026-589.8% ——
CRBUCaribou Biosciences, Inc.LTM Mar 2026-1189.1% +301.7 pp-609.6 pp
HUMAHumacyte, Inc.LTM Mar 2026-4840.8% -3838.0 pp-1239.0 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-36891.1% ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding TNYA) -392.5%+67.7 pp-83.6 pp

Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue4.03M8.71M8.69M8.47M8.44M
Gross Profit(4.03M)(8.71M)(8.69M)(8.47M)(8.44M)
Gross Margin—————
Research & Development54.39M94.54M98.04M86.74M68.61M
Selling, General & Admin14.39M22.37M24.47M20.74M24.72M
Operating Expenses68.78M116.91M122.51M107.48M84.9M
Depreciation & Amortization4.03M8.71M8.69M8.47M8.44M
EBITDA(68.7M)(114.95M)(115.4M)(102.66M)(82.16M)
EBITDA Margin—————
Operating Income(72.81M)(125.62M)(131.19M)(115.95M)(93.33M)
Operating Margin—————
Interest Income108K1.95M7.06M4.74M2.68M
Interest Expense00000
Other Income / Expenses85K1.96M7.11M4.82M2.73M
Income Before Tax(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Net Margin—————
EPS (Basic)(1.69)(2.76)(1.68)(1.31)(0.59)
EPS (Diluted)(1.69)(2.76)(1.68)(1.31)(0.59)
Weighted Avg Shares41.29M44.82M73.79M84.82M152.97M
Weighted Avg Shares (Diluted)41.29M44.82M73.79M84.82M152.97M

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Intrinsic Alpha fair value

Locked

Current Price

$0.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.